Activity of a Novel 1,3-Beta- d -Glucan Synthase Inhibitor, Ibrexafungerp (Formerly SCY-078), against Candida glabrata | Zendy

Mahmoud A. Ghannoum | Zendy; L. Long | Zendy; N. Isham | Zendy; Christopher Hager | Zendy; Rachel Wilson | Zendy; Katyna Borroto–Esoda | Zendy; Stephen Barat | Zendy; D. Angulo | Zendy

Open Access

Activity of a Novel 1,3-Beta- d -Glucan Synthase Inhibitor, Ibrexafungerp (Formerly SCY-078), against Candida glabrata

Author(s) -

Mahmoud A. Ghannoum,

L. Long,

N. Isham,

Christopher Hager,

Rachel Wilson,

Katyna Borroto–Esoda,

Stephen Barat,

D. Angulo

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01510-19

Subject(s) - candida glabrata , echinocandins , broth microdilution , microbiology and biotechnology , echinocandin , biology , glucan , candida albicans , chemistry , biochemistry , antibiotics , antifungal , minimum inhibitory concentration , fluconazole , caspofungin

Ibrexafungerp (formerly SCY-078), a novel glucan synthase inhibitor with oral availability, was evaluated for activity againstCandida glabrata . The susceptibility of clinical strains to ibrexafungerp was determined by microdilution and time-kill assays. The MIC range against wild-type strains was 1 to 2 μg/ml. Ibrexafungerp was also active against the majority of echinocandin-resistant strains.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research